

Contents

| | |
|--|-------------|
| Preface | xvii |
| Section I. Hemostasis Physiology | I |
| CHAPTER 1. Coagulation Pathway and Physiology | 3 |
| Introduction | 3 |
| Constituents of the Hemostatic System | 3 |
| Endothelium | 3 |
| Platelets | 5 |
| Coagulation Proteins | 5 |
| The Extrinsic Pathway and the PT | 6 |
| The Intrinsic Pathway and the aPTT | 7 |
| The PT and aPTT Pathways | 7 |
| Newer Coagulation Model | 7 |
| Regulatory Mechanisms | 10 |
| Operation of the Hemostasis and Thrombosis Pathway | 11 |
| Suggested Reading | 11 |
| CHAPTER 2. Platelet Structure and Function | 13 |
| Platelet Production | 13 |
| Megakaryocyte Development and Maturation | 13 |
| Platelet Production from Megakaryocytes | 15 |
| Platelet Structure | 15 |
| Surface Glycoproteins and Plasma Membrane | 15 |
| Von Willebrand Receptor (GPIb/IX/V) | 15 |
| Collagen Receptors (GPVI and GPIa/IIa) | 16 |
| Adenosine Diphosphate Receptors | 17 |
| Thrombin Receptors (PAR-1 and PAR-4) | 17 |
| Thromboxane Receptor and Prostaglandin Receptors | 18 |
| Fibrinogen Receptor (GPIIb/IIIa) | 18 |
| Platelet Cytoskeleton | 19 |
| Platelet Membrane Systems | 21 |
| Platelet Granules | 21 |
| Alpha Granules | 21 |
| Dense Granules | 22 |
| Platelet Activation | 22 |
| Platelet Adhesion | 23 |
| Role of GPIb/IX/V and von Willebrand Factor | 23 |
| Role of Collagen Receptors | 23 |
| Cytoskeletal Changes | 23 |
| Platelet Activation and Granule Release | 24 |
| Phospholipase Pathway | 24 |
| Cyclooxygenase Pathway | 25 |
| Platelet Granule Release | 25 |

| | |
|--|-----------|
| Platelet Aggregation | 25 |
| Platelet Procoagulant Activity | 26 |
| Suggested Reading | 26 |
| CHAPTER 3. Fibrinolytic System Physiology | 29 |
| History | 29 |
| Proteins and Function | 29 |
| Regulation of Fibrinolysis | 32 |
| Fibrinolysis at the Site of a Thrombus | 33 |
| Suggested Reading | 34 |
| Section 2. Basics of Laboratory Testing in Hemostasis | 35 |
| CHAPTER 4. Sample Collection and Processing | 37 |
| Introduction | 37 |
| Sample Collection Technique for Peripheral Venipuncture | 37 |
| Needle Selection for Venipuncture | 38 |
| Tourniquet Effect | 38 |
| Collection Sets | 38 |
| Specimen Labeling | 38 |
| Blood Collection from Indwelling Lines and Catheters | 39 |
| Blood Collection Tubes and Anticoagulant Considerations | 39 |
| Blood Collection Tubes | 39 |
| Blood Tube Draw Order | 40 |
| Anticoagulant | 40 |
| Volume Effect | 40 |
| Hematocrit Effect | 41 |
| Sample Processing | 42 |
| Preparation of Platelet-Poor Plasma | 42 |
| Effects of Temperature and Time | 42 |
| Factors Affecting Specimen Quality | 44 |
| Suggested Reading | 45 |
| CHAPTER 5. Clinical History in Hemostasis | 47 |
| Introduction | 47 |
| Clinical History in Bleeding Patients | 47 |
| Determine Whether the Patient Has Excess Bleeding | 47 |
| Extent of Bleeding | 47 |
| Duration of Bleeding Abnormality | 49 |
| Type of Bleeding | 49 |
| Bleeding Due to Vascular Disorders | 50 |
| Posttraumatic and Spontaneous Bleeding | 50 |
| Hemarthrosis and Hematomas | 50 |
| Epistaxis | 50 |
| Surgical Procedures | 50 |
| Gingival/Dental Bleeding History | 51 |
| Menstrual History | 51 |
| Obstetric History | 51 |
| Bleeding Due to Organ System Disorders | 51 |
| Medication and Food Habits | 52 |
| Family History | 53 |
| Previous Coagulation Test Results | 54 |
| Pediatric Considerations | 54 |
| Clinical History in Patient with Thrombosis | 54 |
| Age of Onset | 55 |

| | |
|--|-----------|
| Ethnicity | 55 |
| Location and Type of Thrombosis (Venous, Arterial, or Embolic) | 57 |
| Recurrences | 57 |
| Acquired Thrombophilic Risk Factors | 57 |
| Medical History | 57 |
| Malignancy | 58 |
| Obstetrical History and Hormone Therapy | 58 |
| Medication History | 59 |
| Surgery and Trauma | 59 |
| Elevated Levels of Homocysteine | 59 |
| Summary | 59 |
| Suggested Reading | 59 |
| CHAPTER 6. Coagulation Testing | 63 |
| Introduction | 63 |
| Laboratory Measurement of Clot-Based Coagulation Tests | 63 |
| Coagulation Analyzers | 63 |
| Principles of Performance | 63 |
| How to Select and Validate a Coagulation Analyzer | 64 |
| Prothrombin Time | 64 |
| Reagent Considerations | 65 |
| Reporting of Prothrombin Time | 66 |
| Calculation of International Normalized Ratio | 66 |
| Clinical Utility of Prothrombin Time | 70 |
| Point-of-Care Monitors for Oral Anticoagulant Therapy | 70 |
| Activated Partial Thromboplastin Time | 70 |
| Principle | 70 |
| Reagents | 71 |
| Method | 71 |
| Reference Range | 71 |
| Clinical Utility of Activated Partial Thromboplastin Time | 71 |
| Steps to Take in the Evaluation of a Prolonged Activated Partial Thromboplastin Time | 72 |
| Evaluation of Unfractionated Heparin Sensitivity | 72 |
| Thrombin Time | 73 |
| Method | 73 |
| Reagents | 73 |
| Reference Ranges | 73 |
| Clinical Utility of Thrombin Time | 73 |
| Fibrinogen Assay | 74 |
| Clinical Utility of Fibrinogen Assays | 75 |
| Assay of Specific Factors | 75 |
| Principle | 75 |
| Factor II (Prothrombin) | 76 |
| Factors V, VII, and X | 76 |
| Factors VIII, IX, XI, and XII, and High-Molecular-Weight Kininogen and Prekallikrein | 76 |
| False-Positives and False-Negatives in Factor Assays | 77 |
| Factor XIII | 77 |
| Von Willebrand Factor | 78 |
| Mixing Studies | 78 |
| Principle | 78 |
| Technical Considerations | 78 |
| Procedure | 80 |
| Criteria for Interpretation of Mixing Studies | 80 |

| | |
|---|-----------|
| Specific Inhibitor Studies | 80 |
| Bethesda Assay | 80 |
| Nijmegen Modification | 81 |
| Reporting of Results | 81 |
| Establishing Reference Ranges and Validating Coagulation Laboratory Testing | 82 |
| Preatalytic and Postanalytic Considerations | 82 |
| Reference Range | 82 |
| Accuracy | 82 |
| Precision | 83 |
| Linearity | 83 |
| Interfering Conditions | 83 |
| Quality Control | 85 |
| Frequency of QC Testing | 86 |
| Results Reporting | 87 |
| Turnaround Time | 87 |
| Reporting of Results | 87 |
| Quality Assurance | 88 |
| External Proficiency Testing | 88 |
| Summary | 89 |
| Suggested Reading | 89 |
| CHAPTER 7. Platelet Testing | 93 |
| Patient History | 93 |
| Clinical History for Patients with a Bleeding Diathesis | 93 |
| Clinical History for Patients with Thrombosis | 93 |
| Platelet Count, Indices, and Morphology | 94 |
| Sample Collection and Processing Considerations | 94 |
| Test Performance and Interpretation | 95 |
| Bone Marrow Analysis | 96 |
| Sample Collection and Processing Considerations | 96 |
| Bone Marrow Interpretation | 97 |
| Platelet Function Testing | 97 |
| Bleeding Time | 98 |
| PFA-100 | 98 |
| Specimen Considerations | 98 |
| Test Performance and Interpretation | 98 |
| Platelet Aggregation | 101 |
| Specimen Considerations | 101 |
| Test Performance and Interpretation | 101 |
| Plateletworks | 103 |
| VerifyNow | 104 |
| Release Assays | 105 |
| Lumiaggregation | 105 |
| Release Markers | 106 |
| P-selectin | 106 |
| Adhesion Assays | 106 |
| Platelet Adhesion Chambers | 106 |
| Impact | 106 |
| Platelet Mechanical Assays | 106 |
| Hemostasis Analysis System | 106 |
| Whole Blood Viscoelastometry | 107 |
| Flow Cytometry | 107 |
| Platelet Turnover (Platelet Reticulocyte Analysis) | 109 |
| Electron Microscopy | 109 |

| | |
|--|------------|
| Platelet Genetic Testing | 109 |
| ADAMTS-13 Assays | 110 |
| Summary | 110 |
| Suggested Reading | 110 |
| CHAPTER 8. Fibrinolysis Testing | 113 |
| Clinical History Suggesting the Need for Fibrinolytic Testing | 113 |
| Sample Collection and Processing for Fibrinolytic Testing | 113 |
| D-Dimer and Fibrin Split Product Assays | 115 |
| Plasminogen Assays | 117 |
| Alpha 2-Antiplasmin Assays | 118 |
| Tissue Plasminogen Activator Assays | 118 |
| Plasminogen Activator Inhibitor-1 Assays | 120 |
| Global Tests of Fibrinolysis | 121 |
| Lipoprotein (a) | 122 |
| Research Assays | 122 |
| Suggested Reading | 123 |
| CHAPTER 9. Thrombophilia Testing | 125 |
| Introduction | 125 |
| Protein C | 125 |
| Protein C Functional Assays | 125 |
| Clotting Method | 125 |
| Spectrophotometric Method | 126 |
| Protein C Antigen Assays | 127 |
| Protein S | 128 |
| Protein S Functional Assays | 129 |
| Protein S Activity Assays | 129 |
| Protein S Antigenic Assays | 129 |
| Antithrombin | 130 |
| Antithrombin Assays | 131 |
| Antithrombin Functional Assays | 131 |
| Antithrombin Antigen Assay | 131 |
| Activated Protein C Resistance | 131 |
| Activated Protein C Resistance Assays | 131 |
| Factor VII Activity | 132 |
| Fibrinogen Abnormalities | 133 |
| Lupus Anticoagulant | 133 |
| Factor V Leiden and Prothrombin G20210A Mutations | 133 |
| Plasma Homocysteine Concentration | 134 |
| Global Tests of Hypercoagulability | 135 |
| Endogenous Thrombin Potential | 135 |
| Undiluted Activated Protein C Resistance | 136 |
| Activated Partial Thromboplastin Time | 136 |
| Activation and Degradation Peptides | 136 |
| Conclusion | 137 |
| Suggested Reading | 137 |
| Section 3. Algorithmic Approach to Bleeding Disorders | 141 |
| CHAPTER 10. Abnormal Activated Partial Thromboplastin Time | 143 |
| Introduction | 143 |
| Clinical Etiologies | 143 |
| Medications | 143 |
| Coagulation Factor Deficiency Associated with Significant Hemorrhage | 144 |

| | |
|--|------------|
| Von Willebrand Disease | 144 |
| Factor VIII Deficiency | 145 |
| Factor IX Deficiency | 145 |
| Factor XI Deficiency | 145 |
| Other Inherited and Acquired Deficiencies | 146 |
| Coagulation Factor Deficiencies Not Associated with Bleeding | 146 |
| Lupus Anticoagulant | 146 |
| Specific Coagulation Factor Inhibitors | 146 |
| Alloantibodies in Hemophilic Patients | 146 |
| Autoantibodies to Factor VIII and Other Factors | 147 |
| Spurious Causes of an Elevated aPTT | 147 |
| Laboratory Testing | 148 |
| Accelerated aPTT | 150 |
| Summary | 151 |
| Suggested Reading | 151 |
| <i>Case Study</i> | 143 |
| CHAPTER 11. Prolonged Prothrombin Time | 153 |
| Introduction | 153 |
| Differential Diagnosis of a Corrected Mixing Study | 153 |
| Dilutional Coagulopathy | 154 |
| Disseminated Intravascular Coagulation | 155 |
| Drugs | 155 |
| Warfarin | 155 |
| Factor Deficiency | 155 |
| Factor II Deficiency | 155 |
| Factor V Deficiency | 156 |
| Factor V and Factor VIII Deficiency, Combined | 157 |
| Factor VII Deficiency | 157 |
| Factor X Deficiency | 157 |
| Fibrinogen Deficiency | 158 |
| Vitamin K-Dependent Coagulation Factor Deficiency, Hereditary | 158 |
| Liver Disease | 159 |
| Superwarfarin Poisoning | 159 |
| Vitamin K Deficiency | 159 |
| Newborns | 159 |
| Adults | 160 |
| Differential Diagnosis of a Noncorrected Mixing Study | 160 |
| Drugs | 160 |
| Direct Thrombin Inhibitors | 160 |
| Heparin | 160 |
| Factor Inhibitors | 161 |
| Factor II Inhibitor | 161 |
| Factor V Inhibitor | 161 |
| Factor VII Inhibitor | 162 |
| Factor X Inhibitor | 162 |
| Lupus Anticoagulant | 162 |
| Algorithm | 162 |
| Suggested Reading | 164 |
| <i>Case Studies: Prolonged PT with Normal aPTT; Prolonged PT with Prolonged aPTT</i> | 154 |
| CHAPTER 12. Normal Prothrombin Time and Activated Partial Thromboplastin Time | 169 |
| Introduction | 169 |
| Clinical Evaluation | 169 |

| | |
|--|------------|
| False-Negative (Normal) PT and aPTT | 169 |
| Patient-Specific Causes | 170 |
| Preanalytic Causes | 170 |
| Analytic Causes | 170 |
| Postanalytic Causes | 171 |
| Additional Testing | 171 |
| Primary Hemostasis Defects | 171 |
| Secondary Hemostasis Defects | 171 |
| Factor Assays | 171 |
| Factor XIII Deficiency | 171 |
| Fibrinolysis Defects | 172 |
| Vascular Disorders | 172 |
| Algorithm | 173 |
| Suggested Reading | 173 |
| <i>Case Study</i> | 170 |
| CHAPTER 13. Fibrinolytic Bleeding Disorders | 175 |
| Clinical Evaluation of Fibrinolytic Bleeding Disorders | 175 |
| Plasminogen Activator Inhibitor-1 Deficiency | 175 |
| Alpha-2 Antiplasmin Deficiency | 177 |
| Acquired Causes of Fibrinolytic Bleeding | 177 |
| Disseminated Intravascular Coagulation | 178 |
| Suggested Reading | 182 |
| <i>Case Study: Postoperative Bleeding and PAI-1 Deficiency</i> | 175 |
| <i>Case Study: Tissue Plasminogen Activator Release During Renal Transplantation</i> | 177 |
| <i>Case Study: DIC Associated with Gastric Carcinoma</i> | 178 |
| CHAPTER 14. Platelet Disorders | 185 |
| Introduction | 185 |
| Platelet Dysfunction with Normal Platelet Count (Qualitative Platelet Disorders) | 185 |
| Glycoprotein Disorders | 189 |
| Glanzmann Thrombasthenia (GPIIb/IIIa Deficiency) | 189 |
| Glycoprotein Ib/IX/V (Bernard-Soulier Syndrome) | 190 |
| Platelet-Type von Willebrand Disease | 190 |
| Glycoprotein IV | 191 |
| Collagen Receptor Disorders (GPIa/IIa and GPVI) | 191 |
| Adenosine Diphosphate Receptor Abnormalities | 191 |
| Platelet Release Defects | 191 |
| Storage Pool Disorders (Alpha and Dense Granule Disorders) | 191 |
| Signal Transduction Disorders | 194 |
| Disorders of Platelet Procoagulant Activity (Scott Syndrome) | 195 |
| Platelet Disorders with Thrombocytosis | 195 |
| Reactive Thrombocytosis | 195 |
| Myeloproliferative Disorders Associated with Thrombocytosis | 196 |
| Platelet Disorders with Thrombocytopenia | 196 |
| Thrombocytopenia with Increased Platelet Size | 197 |
| Macrothrombocytopenias with Neutrophilic Inclusions (MYH9 Disorders) | 197 |
| Bernard-Soulier Syndrome | 199 |
| The Gray Platelet Syndrome (Alpha Granule Storage Pool Disorder) | 200 |
| Thrombocytopenia with Decreased Platelet Size | 201 |
| Wiskott-Aldrich Syndrome and X-Linked Thrombocytopenia | 201 |
| Thrombocytopenia with Normal Platelet Size | 201 |
| Peripheral Platelet Destruction | 202 |
| Immune Destructive Thrombocytopenias | 202 |

| | |
|---|------------|
| Nonimmune Destructive Thrombocytopenias | 204 |
| Decreased Platelet Production | 207 |
| Hereditary Thrombocytopenias with Decreased Platelet Production | 207 |
| Acquired Thrombocytopenias with Decreased Platelet Production | 208 |
| Platelet Dysfunction Associated with Other Illnesses | 208 |
| Platelet Disorders Associated with Thrombosis or Platelet Activation | 208 |
| Platelet Activation | 209 |
| Genetic Polymorphisms Associated with Thrombosis and Cardiovascular Disease | 209 |
| Cardiovascular Devices | 210 |
| Summary | 210 |
| Suggested Reading | 211 |
| <i>Case Study</i> | 185 |
| CHAPTER 15. Abnormal Thrombin Time | 217 |
| Introduction | 217 |
| Clinical Indications | 217 |
| Differential Diagnosis | 218 |
| Amyloidosis | 218 |
| Autoantibodies | 219 |
| Drugs | 219 |
| Bovine Thrombin, Topical | 219 |
| Direct Thrombin Inhibitors | 219 |
| Heparin | 219 |
| Plasminogen Activators | 220 |
| Volume Expanders | 220 |
| Fibrin Degradation Products | 220 |
| Fibrinogen Abnormalities | 220 |
| Dysfibrinogenemia | 220 |
| Hypofibrinogenemia | 222 |
| Afibrinogenemia | 222 |
| Hyperfibrinogenemia | 222 |
| Radiocontrast Agents | 222 |
| Algorithm | 222 |
| Suggested Reading | 222 |
| <i>Case Study</i> | 217 |
| CHAPTER 16. Von Willebrand Disease | 225 |
| Introduction | 225 |
| Von Willebrand Factor | 225 |
| Clinical Features | 225 |
| Classification | 226 |
| Inheritance | 227 |
| Laboratory Testing | 227 |
| Laboratory Findings in Type 1 von Willebrand Disease | 230 |
| Laboratory Findings in Type 2 von Willebrand Disease | 230 |
| Laboratory Findings in Type 3 von Willebrand Disease | 231 |
| The Molecular Basis of von Willebrand Disease | 231 |
| Acquired von Willebrand Disease | 232 |
| Treatment | 233 |
| Suggested Reading | 234 |
| Section 4. Algorithmic Approach to Thrombophilic Disorders | 237 |
| CHAPTER 17. Arterial and Venous Thrombosis in Adults | 239 |
| Introduction | 239 |

| | |
|---|------------|
| General Considerations | 240 |
| Consent and Counseling | 240 |
| Assay Calibration, Reference Range, and Assay Reliability | 240 |
| Combined Deficiency | 241 |
| Testing for Thrombophilic Risk in Patients with Venous or Arterial Thrombosis | 241 |
| Thrombophilic Risk Factor Test Selection in Provoked and Spontaneous Venous Thromboembolism | 241 |
| What Tests Should Be Performed? | 242 |
| When Should Thrombophilia Testing Be Performed? | 244 |
| Recommendations for Testing of Individual Analytes | 244 |
| Protein C, Protein S, and Antithrombin Deficiency | 244 |
| Factor V Leiden and Prothrombin G20210A Mutations | 245 |
| Hyperhomocysteinemia and High Concentrations of Factor VIII | 246 |
| Acquired Thrombophilic Risk Factors | 246 |
| Antiphospholipid Antibodies | 246 |
| Heparin-Induced Thrombocytopenia | 246 |
| Thrombophilic Risk Factor Test Selection in Arterial Thrombosis | 247 |
| Antiphospholipid Antibodies (Lupus Anticoagulant and Anticardiolipin Antibodies) | 248 |
| C-Reactive Protein | 248 |
| Lipoprotein (a) | 248 |
| Homocysteine | 249 |
| Prothrombin G20210A Mutation | 250 |
| Factor V Leiden (Activated Protein C Resistance) | 250 |
| Deficiencies of Protein C, Protein S, and Antithrombin | 250 |
| Coagulation Factors | 251 |
| Heparin-Induced Thrombocytopenia | 251 |
| Thrombophilic Risk Factor Test Selection in Neurovascular Thrombosis | 251 |
| Antiphospholipid Antibodies (Lupus Anticoagulant and Anticardiolipin Antibodies) | 251 |
| Lipoprotein (a) | 251 |
| Homocysteine | 252 |
| Prothrombin G20210A Mutation | 253 |
| Factor V Leiden (Activated Protein C Resistance) | 253 |
| Deficiencies of Protein C, Protein S, and Antithrombin | 253 |
| Heparin-Induced Thrombocytopenia | 254 |
| Suggested Reading | 254 |
| <i>Case Studies</i> | 242 |
| CHAPTER 18. Unique Issues of Thrombophilia in Women and Children | 257 |
| Introduction | 257 |
| Pregnancy and Hormonal Therapy | 257 |
| Oral Contraceptives and Risk of Venous Thromboembolism | 257 |
| Hormone Replacement Therapy and Venous Thromboembolism | 258 |
| Pregnancy-Related Venous Thromboembolism | 259 |
| Thrombophilia and Recurrent Fetal Loss | 259 |
| Thrombophilia and Late Gestational Vascular Complications | 260 |
| Treatment of Pregnant Women with Thrombophilias | 261 |
| Thrombophilia in Neonates, Infants, and Children | 262 |
| Description of the Problem | 262 |
| Testing for Thrombophilia in Children | 263 |
| Suggested Reading | 265 |
| <i>Case Study</i> | 258 |
| <i>Case Study</i> | 262 |

| | |
|--|------------|
| CHAPTER 19. Laboratory Diagnosis of Inherited Thrombophilia | 267 |
| Introduction | 267 |
| Algorithmic Approach to Laboratory Diagnosis of Thrombophilic Risk Factors | 267 |
| Protein C | 268 |
| Protein S | 270 |
| Antithrombin | 271 |
| Factor VIII | 272 |
| Activated Protein C Resistance and Factor V Leiden | 273 |
| Prothrombin G20210A Mutation | 274 |
| Homocysteine | 274 |
| Thrombophilia Testing, Duration of Anticoagulation Therapy, and Screening First-Degree Relatives | 274 |
| Suggested Reading | 277 |
| <i>Case Study</i> | 268 |
| | |
| CHAPTER 20. Fibrinolytic Thrombotic Disorders | 279 |
| Introduction | 279 |
| Thrombosis and Defects of Fibrinolysis | 279 |
| Plasminogen Deficiency | 279 |
| Tissue Plasminogen Activator Deficiency | 279 |
| Plasminogen Activator Inhibitor Excess | 280 |
| Alpha 2-Antiplasmin Excess | 280 |
| Euglobulin Clot Lysis Time Assay | 280 |
| Thrombin-Activatable Fibrinolysis Inhibitor | 280 |
| Dysfibrinogenemia | 281 |
| Factor XII (Hageman Factor) Deficiency | 281 |
| Lipoprotein (a) Excess | 281 |
| Disseminated Intravascular Coagulation | 281 |
| Antifibrinolytic Medications | 282 |
| The Role of D-dimer in Excluding Venous Thromboembolism | 282 |
| D-Dimer Testing | 283 |
| Variations in the Types of D-Dimer Assays | 283 |
| Selecting the Appropriate Cutoff and Units for Excluding Venous Thromboembolism | 284 |
| Summary | 284 |
| Suggested Reading | 284 |
| <i>Case Study</i> | 282 |
| | |
| CHAPTER 21. Heparin-Induced Thrombocytopenia | 287 |
| Introduction | 287 |
| Clinical Presentation | 287 |
| Pathophysiology | 289 |
| Clinical Laboratory Diagnosis and Algorithm | 289 |
| Treatment | 292 |
| Suggested Reading | 293 |
| <i>Case Study</i> | 287 |
| | |
| CHAPTER 22. Antiphospholipid Antibodies | 295 |
| Introduction | 295 |
| Laboratory Testing for Antiphospholipid Antibodies | 295 |
| Lupus Anticoagulant Testing Considerations and International Society on Thrombosis and Haemostasis (ISTH) Criteria | 295 |
| Preanalytical Variables | 297 |
| Testing for a Lupus Anticoagulant | 297 |
| Exclusion of Other Abnormalities (Factor Inhibitors) | 300 |
| Indeterminate Results: When Samples Do Not Meet All International Society on Thrombosis and Haemostasis Criteria | 301 |

| | |
|---|------------|
| Anticardiolipin Antibody Testing and Other Antiphospholipid Antibody Immunoassays | 301 |
| Clinical Features and Diagnosis | 301 |
| Monitoring Anticoagulation in Patients with Lupus Anticoagulants | 303 |
| Suggested Reading | 303 |
| <i>Case Study</i> | 296 |
| Section 5. Antiplatelet and Anticoagulant Drugs | 305 |
| CHAPTER 23. Antithrombotic Agents | 307 |
| Introduction | 307 |
| Target Therapeutic Range and Monitoring Considerations | 308 |
| Common Clinical Settings Where Antithrombotic Agents Are Used | 309 |
| Acute Venous Thromboembolism | 309 |
| Prophylaxis for Venous Thromboembolism | 309 |
| Prophylaxis in Patients with Atrial Fibrillation | 309 |
| Acute Coronary Syndromes | 309 |
| Peripheral Vascular and Cerebrovascular Disease | 310 |
| Extracorporeal Circulation | 310 |
| Implantation of Mechanical Heart Valves | 310 |
| Effects on Tests of Hemostasis | 310 |
| Summary | 310 |
| Suggested Reading | 311 |
| CHAPTER 24. Anticoagulant Agents | 313 |
| Introduction | 313 |
| Unfractionated Heparin | 313 |
| Laboratory Monitoring of Unfractionated Heparin | 315 |
| Acute Venous Thromboembolism | 316 |
| Acute Coronary Syndromes | 319 |
| Renal Dialysis, Percutaneous Coronary Intervention, and Cardiopulmonary Bypass | 320 |
| Low-Molecular-Weight Heparins | 320 |
| Laboratory Monitoring of Low-Molecular-Weight Heparin | 320 |
| Fondaparinux | 321 |
| Laboratory Monitoring of Fondaparinux | 322 |
| Hirudins (Peptide Direct Thrombin Inhibitors) | 322 |
| Laboratory Monitoring of Hirudin Analogues | 324 |
| Argatroban | 325 |
| Laboratory Monitoring of Argatroban | 326 |
| Oral Anticoagulants | 327 |
| Laboratory Monitoring of Vitamin K Antagonists | 328 |
| Suggested Reading | 329 |
| CHAPTER 25. Antiplatelet Agents | 333 |
| Introduction | 333 |
| Parenteral Agents | 333 |
| Glycoprotein IIb/IIIa Inhibitors | 333 |
| Mechanism of Action | 333 |
| Effect on Platelet Function Tests | 336 |
| Clinical Uses | 336 |
| Role of Monitoring | 336 |
| Special Issues | 337 |
| Oral Agents | 337 |
| Aspirin | 337 |
| Mechanism of Action | 337 |
| Clinical Uses | 337 |

| | |
|--|------------|
| Laboratory Tests Used to Assess Effect | 338 |
| Laboratory Monitoring | 339 |
| Thienopyridines | 340 |
| Mechanism of Action | 340 |
| Clinical Uses | 341 |
| Laboratory Monitoring | 342 |
| Clopidogrel Resistance | 342 |
| Dipyridamole | 342 |
| Mechanism of Action | 342 |
| Clinical Uses | 343 |
| Monitoring Issues | 343 |
| Iloprost | 344 |
| Cilostazol | 344 |
| Mechanism of Action | 344 |
| Clinical Uses | 344 |
| Monitoring Issues | 344 |
| New Antiplatelet Drugs in Development | 344 |
| Antiplatelet Effect of Other Drugs and Herbal Remedies | 345 |
| Summary | 346 |
| Suggested Reading | 346 |
| Section 6. Appendices and Index | 353 |
| Appendix A. Abbreviations | 355 |
| Appendix B. Example Reference Ranges | 359 |
| Index | 361 |

List of Algorithms

| | |
|--|-----|
| Detection of Interfering Drug Effects Prior to Performing aPTT Mixing Studies | 79 |
| Platelet Functional Analyzer-100 (PFA-100) Testing | 99 |
| Thrombophilia Risk Factor Screening | 126 |
| Evaluation of a Prolonged aPTT | 148 |
| Evaluation of Slight Prolongation of the aPTT | 149 |
| Investigation of a Prolonged PT with or without a Prolonged aPTT | 163 |
| Diagnosis of a Bleeding Etiology with a Normal PT and aPTT | 172 |
| Use of D-Dimer Assay to Assess DIC | 180 |
| Distinguishing Platelet Abnormalities with a Normal or Increased Platelet Count | 187 |
| Platelet Aggregation Studies to Distinguish Between Acquired Platelet Disorders | 187 |
| Distinction of Platelet Disorders with Thrombocytopenia with Increased or Decreased Platelet Size | 197 |
| Diagnosis of Thrombocytopenic Disorders Associated with Increased Platelet Destruction or Decreased Production | 202 |
| Evaluation of an Abnormal Thrombin Time | 221 |
| Inherited Thrombophilia Testing | 244 |
| Inherited Thrombophilia Risk Factor Confirmatory Testing | 267 |
| Protein C Testing | 269 |
| Protein S Testing | 270 |
| Antithrombin Testing | 272 |
| Activated Protein C Resistance/Factor V Leiden Testing | 273 |
| Homocysteine Testing | 275 |
| Diagnosis of Heparin-Induced Thrombocytopenia, Typical Onset | 290 |
| Diagnosis of Heparin-Induced Thrombocytopenia, Rapid Onset | 291 |
| Diagnosis of the Presence of a Lupus Anticoagulant | 298 |